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SAOBJECTIVES The purpose of this analysis was to assess 5-year outcomes of transcatheter aortic valve implantation
(TAVI) using the current technology of the self-expanding CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota).
BACKGROUND There is a paucity of evidence on long-term durability of currently available transcatheter heart valves.
METHODS Starting in June 2007, all consecutive patients with severe aortic stenosis undergoing TAVI with the third-
generation 18-F CoreValve device in 8 Italian centers were prospectively included in the ClinicalService Project. For the
purposes of this study, we included only consecutive patients with 5-year follow-up data available (n ¼ 353) treated from
June 2007 to August 2009. All outcomeswere reported according to VARC (Valve Academic Research Consortium)-1 criteria.
RESULTS All-cause mortality rates at 1, 2, 3, 4, and 5 years were 21%, 29%, 38%, 48%, and 55.0%, respectively.
Cardiovascular mortality rates at 1, 2, 3, 4, and 5 years were 10%, 14%, 19%, 23%, and 28.0%, respectively. The overall
neurological event rate at 5 years was 7.5%, of which more than two-thirds occurred early after the procedure. During
follow-up, there were 241 rehospitalizations for cardiovascular reasons in 164 (46%) patients. Among all rehospitali-
zations, acute heart failure was the most frequently reported (42.7%), followed by requirement of permanent pacemaker
implantation (17.4%). On echocardiography, mean transaortic gradients decreased from 55.6  16.8 mm Hg (pre-TAVI)
to 12.8  10.9 mm Hg (5-year post-TAVI) (p < 0.001). Late prosthesis failure occurred in 5 cases (1.4%); among these,
redo TAVI was successfully carried out in 2 patients (0.6%) presenting with symptomatic prosthesis restenosis. The
remaining 3 cases of prosthesis failure did not undergo further invasive interventions. Ten patients (2.8%) showed late
mild stenosis with a mean transaortic gradient ranging from 20 to 40 mm Hg. No other cases of structural or
nonstructural valvular deterioration were observed. Valve thrombosis or late valve embolization were not reported.
CONCLUSIONS TAVI with the currently adopted CoreValve generation was associated with sustained clinical outcomes
up to 5-year follow-up, with a low rate (1.4%) of signiﬁcant prosthetic valve degeneration. The procedure appears to be
an adequate and lasting resolution of aortic stenosis in selected high-risk patients. (J Am Coll Cardiol Intv 2015;8:1084–91)
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
HR = hazard ratio
IQR = interquartile range
IRR = incidence rate ratio
MR = mitral regurgitation
TAVI = transcatheter aortic
implantation
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1085T ranscatheter aortic valve implantation (TAVI)has become an accepted and less invasivetreatment alternative for high-risk surgical
patients with severe aortic stenosis. Short- and
medium-term outcomes have been encouraging (1–5).
However, data on long-term clinical outcomes, valve
durability, and structural integrity remain scarce (6–
8). Although the 5-year outcomes of balloon-
expandable Edwards-SAPIEN prosthesis (Edwards
Lifesciences, Irvine, California) were recently reported
(6), the longest follow-up with the CoreValve (Med-
tronic Inc., Minneapolis, Minnesota) device thus far
is 3 years, as reported by 2 different groups (7).SEE PAGE 1092The paucity of evidence on long-term durability of
currently available transcatheter heart valves is one
of the main issues that prevents TAVI from being
used in younger and lower-risk patients. The objec-
tive of this analysis was to assess 5-year outcomes
of TAVI using the current technology of the self-
expanding CoreValve prosthesis.
METHODS
PATIENT POPULATION. Starting in June 2007, all
consecutive patients with severe aortic stenosis un-
dergoing TAVI with the third-generation 18-F Core-
Valve device in 8 Italian centers were prospectively
included in the ClinicalService Project (NCT01007474).
Details of the ClinicalService Project’s design have
been previously described (9). Brieﬂy, this is a nation-
based clinical data repository and medical care
project aimed at describing and improving the use of
implantable devices in Italian clinical practice. The
project was approved by each site’s institutional re-
view board or medical director and conforms to the
principles outlined in the Declaration of Helsinki.
Each patient signed an informed consent for data
collection and analysis. Clinical and echocardio-
graphic follow-up were performed according to each
center’s clinical practice by clinical visits or telephone
contacts. All events were site reported. For the pur-
poses of this study, we included in this analysis only
consecutive patients with 5-year follow-up data
available.Scientiﬁc. Dr. Ettori has served as a medical proctor for Medtronic. Dr. Latib
has served as a consultant for Direct FlowMedical. Dr. Colombo is a minor sh
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Manuscript received February 19, 2015; accepted March 1, 2015.PROCEDURE. Design features of the Cor-
eValve prosthesis and technical details of the
procedure have been previously described
(10,11). The CoreValve prosthesis, available in
the 26- and 29-mm sizes, was implanted us-
ing the transfemoral and subclavian ap-
proaches with an 18-F delivery catheter. All
procedures were performed under local
anesthesia (with or without additional seda-
tion and/or analgesia) or general anesthesia
and endotracheal intubation, under ﬂuoroscopic
guidance.
STATISTICAL ANALYSIS AND DEFINITIONS. Des-
criptive statistics were summarized as mean  SD
for normally distributed continuous variables or
otherwise as median and 25th to 75th percentile
(interquartile range [IQR]), whereas for categorical
variables, absolute and relative frequencies are re-
ported. Survival analysis has been carried out with
the Kaplan-Meier method, reporting incidence of
event at each year. Landmark analyses at 30 days
and 5 years were also performed, and incidence of
the outcomes was assessed with the Kaplan-Meier
method at both landmark points. Univariate Cox
Regression has been used to identify univariate pre-
dictors of events from the major baseline and proce-
dural characteristics; all of the variables with a
univariate p < 0.15 have been subsequently tested in
a multivariate Cox regression to identify independent
predictors of the event. Results of the Cox regression
are reported as hazard ratio (HR) together with 95%
conﬁdence interval (CI). To identify predictors of
heart failure hospitalizations, univariate Poisson
regression models were carried out, and then all
resulting variables with a p value <0.15 were put into
the multivariable model to identify independent
predictors. The Akaike information criterion was used
to identify the best subset of predictors. Incidence
rate ratio (IRR), together with 95% CI, is reported as a
result of the Poisson regression.
For statistical analysis, SAS version 9.3 for Win-
dows (SAS Institute Inc., Cary, North Carolina) was
used. All outcomes were reported according to
VARC (Valve Academic Research Consortium)-1
criteria (12).
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TABLE 1 Baseline Characteristics (n ¼ 353)
Clinical Variables
Age, yrs 81.5  6.3
Males 44.5 (157/353)
Logistic EuroScore, % 21.5 (15–31)
STS score, %
Mean 9.5  10.0
Median 5.8 (4–11)
Creatinine, mg/dl 1.2 (1–2)
Chronic renal failure 11.1 (37/333)
NYHA functional class III to IV 70.0 (247/353)
Hypertension 75.6 (267/353)
Diabetes mellitus 30.3 (107/353)
Prior ischemic event 7.4 (26/353)
Prior stroke 5.1 (18/353)
Permanent AF 1.4 (5/353)
Prior MI 21.8 (77/353)
Prior PCI 30.0 (106/353)
Prior SAVR 1.1 (4/353)
PVD 27.2 (96/353)
COPD* 25.8 (91/353)
Prior CABG 15.3 (54/353)
Prior PPM 11.2 (37/331)
Echocardiographic Variables
Mean aortic gradient, mm Hg 55.6  16.8
Aortic regurgitation $ moderate 33.8 (112/331)
Mitral regurgitation $ moderate 41.7 (143/343)
LVEF, % 50.6  12.3
LVEF <35% 13.0 (46/353)
LVEF 35%–55% 48.7 (172/353)
sPAP >60 mm Hg 9.1 (32/353)
Values are mean  SD, % (n/N), or median (25th–75th percentile). *Deﬁned as
long-term use of bronchodilators or steroids for lung disease.
AF ¼ atrial ﬁbrillation; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic
obstructive pulmonary disease; LVEF ¼ left ventricular ejection fraction; MI ¼
myocardial infarction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous
coronary intervention; PPM ¼ permanent pacemaker; PVD ¼ peripheral artery
disease; SAVR ¼ surgical aortic valve replacement; sPAP ¼ systolic pulmonary
artery pressure; STS ¼ Society of Thoracic Surgery.
TABLE 2 In-Hospital Outcomes (n ¼ 353)
Death from any cause 6.5 (23/353)
Cardiovascular death 4.0 (14/353)
Any stroke 2.3 (8/353)
Major stroke 1.7 (6/353)
Minor stroke 0.6 (2/353)
Life-threatening bleeding 5.9 (21/353)
Major bleeding 20.7 (73/353)
AKI 1 29.0 (85/293)
AKI 2 1.0 (3/293)
AKI 3 0.3 (1/293)
New PPM 23.7 (75/316)*
PVR more than mild 23.6 (81/343)
Antiplatelet therapy at discharge
SAPT 19.1 (63/330)
DAPT 71.5 (236/330)
OAT 0.9 (3/330)
SAPT þ OAT 6.7 (22/330)
DAPT þ OAT 0.9 (3/330)
Unknown 0.9 (3/330)
Values are % (n/N). *Denominator represents the number of patients without PPM
at baseline.
AKI ¼ acute kidney injury; DAPT ¼ dual antiplatelet therapy; OAT ¼ oral anti-
coagulant; PPM ¼ permanent pacemaker; PVR ¼ paravalvular regurgitation;
SAPT ¼ single antiplatelet therapy.
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1086RESULTS
POPULATION. A total of 353 patients (mean age
81.5  6.3 years) treated consecutively with TAVI
with CoreValve from June 2007 to August 2009
formed the analysis group. Baseline demographic,
clinical, and echocardiographic characteristics are
listed in Table 1. All patients had severe symptomatic
aortic stenosis (mean transaortic pressure gradients
55.6  16.8 mm Hg). Predicted 30-day mortality
21.5% (IQR: 15% to 31%) by Logistic EuroSCORE and
5.8% (IQR: 4% to 11%) by Society of Thoracic Surgery
(STS) mortality score. The majority of patients
(n ¼ 247; 70.0%) were in New York Heart Association
(NYHA) functional class III or IV before the
procedure.PROCEDURAL AND IN-HOSPITAL OUTCOMES. Trans-
femoral access was used in 317 patients (89.8%); in
36 patients (10.2%) in whom the transfemoral
approach was unfeasible, a trans-subclavian access
was employed. The 26- and 29-mm CoreValve
ReValving Systems were implanted in 216 (61.4%) and
136 (38.6%) patients, respectively. In-hospital out-
comes are listed in Table 2. All-cause and cardiovas-
cular mortality were 6.5% and 4.0%, respectively. A
permanent pacemaker was implanted in 23.7% (75 of
316) of patients, in most cases due to permanent or
intermittent third-degree atrioventricular block. Life-
threatening bleeding occurred in 21 patients (5.9%)
and cerebrovascular events in 8 patients (2.3%).
5-YEAR OUTCOMES. Clinical follow-up was available
in all patients (100%). A total of 187 (53%) patients
died during a median follow-up of 47 months (IQR: 16
to 70 months). All-cause mortality rates at 1, 2, 3, 4,
and 5 years were 21%, 29%, 38%, 48%, and 55.0%,
respectively (Figure 1A). Cardiovascular mortality
rates at 1, 2, 3, 4, and 5 years were 10%, 14%, 19%,
23%, and 28.0%, respectively (Figure 1B).
When patients with 30-day mortality were
excluded, 5-year all-cause and cardiovascular mor-
tality were 51.0% and 25.0%, respectively, as shown
by the landmark analysis (Figures 2A and 2B).
The presence of moderate or severe paravalvular
regurgitation after TAVI was associated with
FIGURE 1 Kaplan-Meier Analysis
Kaplan-Meier percentage of (A) mortality rate and (B) rate of cardiovascular mortality at 5-year follow-up. CI ¼ conﬁdence interval.
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1087increased late mortality compared with none or mild
(63% vs. 51%; p ¼ 0.034) (Online Figure 1). The overall
neurological event rate at 5 years was 7.5%, of which
more than two-thirds occurred early after the proce-
dure (Figure 3); antiplatelet/anticoagulant therapy
taken by the patients at the moment of stroke/tran-
sient ischemic attack is reported in Online Appendix
Table 1.
During follow-up, there were 241 rehospitaliza-
tions for cardiovascular reasons in 164 (46%) patients.
Among all rehospitalizations, acute heart failure
was the most frequently reason reported (42.7%),
followed by requirement of permanent pacemaker
implantation (17.4%) (Table 3).
After adjustment for confounders by multivariable
analysis, moderate/severe mitral regurgitation (MR)
(adjusted HR: 1.49; 95% CI: 1.02 to 2.17; p ¼ 0.038),
baseline NYHA functional class III or IV (adjusted HR:
1.62; 95% CI: 1.04 to 2.52; p ¼ 0.033), and STS score
(adjusted HR: 1.02; 95% CI: 1.01 to 1.04; p ¼ 0.003)
were found to be independently associated with
all-cause mortality. Independent predictors of car-
diovascular mortality were chronic obstructive pul-
monary disease (COPD) (adjusted HR: 2.13; 95% CI:
1.07 to 4.23; p ¼ 0.031) and moderate/severe MR
(adjusted HR: 2.87; 95% CI: 1.47 to 5.61; p ¼ 0.002)
(Table 4).
At the Poisson regression; moderate/severe MR
(IRR: 2.06; 95% CI: 1.12 to 3.78; p ¼ 0.020), chronic
renal insufﬁciency (IRR: 2.77; 95% CI: 1.05 to 7.34;
p ¼ 0.040), diabetes mellitus (IRR: 1.86; 95% CI: 1.01
to 3.44; p ¼ 0.047), and COPD (IRR: 2.67; 95% CI: 1.42to 5.02; p ¼ 0.002) were found to be independently
associated with an increased risk of repeated hospi-
talization due to heart failure (Table 5).
PROSTHESIS PERFORMANCE. The graph depicting
prosthesis performances at follow-up is reported in
Figure 4. On transthoracic echocardiography, mean
pressure gradients decreased from 55.6  16.8 mm Hg
(pre-TAVI) to 10.3  6.5 mm Hg (in-hospital post-
TAVI) (p < 0.001). Transaortic gradient remained
steady over the subsequent 4 years and slightly
increased at 5 years (12.8  10.9 mm Hg). The degree
of PVR over time is depicted in Online Figure 2. One
patient underwent early redo TAVI with a SAPIEN XT
valve at day 6 due to severe paravalvular regurgita-
tion. Late prosthesis failure occurred in 5 cases
(1.4%); among these, redo TAVI (valve-in-valve), was
successfully carried out in 2 patients (0.6%) present-
ing with symptomatic prosthesis restenosis at days
1,693 and 1,465, respectively. The other 3 cases of
prosthesis failure did not undergo further invasive
interventions: 1 case of endocarditis with severe
aortic regurgitation (day 1,681) who died due to
noncardiovascular reasons, 1 case of asymptomatic
valve degeneration with severe insufﬁciency (day
1,674), and 1 case of worsening of paravalvular
regurgitation from moderate to severe (day 355) who
is alive at 2-year follow-up. Ten other patients (2.8%)
showed late mild stenosis with a mean transaortic
gradient ranging from 20 to 40 mm Hg. No other cases
of structural or nonstructural valvular deterioration
were observed. Valve thrombosis or late valve
embolization were not reported.
FIGURE 2 Landmark Analysis
Landmark analysis for (A)mortality rate and (B) rate of cardiovascular mortality. Two time points were considered as landmarks: 30 days and 5
years. CI ¼ conﬁdence interval.
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1088DISCUSSION
TAVI has been validated by 2 randomized clinical
trials as “at least” noninferior to surgery in patients
with aortic stenosis who are at high risk for conven-
tional aortic valve replacement (1–3). The most recent
guidelines have consolidated the role of TAVI as an
important alternative in the treatment of this impor-
tant valve heart disease (13). However, although
many studies have shown positive short and mid-
term effectiveness of TAVI (1–5), there is still a
paucity of data on the long-term durability of current
TAVI prostheses (6–8).
The present multicenter analysis describes the
outcomes of a cohort of TAVI patients with the
longest follow-up using the currently adopted self-
expanding CoreValve ReValving System device.We demonstrated favorable long-term outcomes,
with a 5-year survival rate of 45% and freedom
from re-hospitalization for cardiac reasons of 54%.
Valve performance was excellent up to 5 years after
implantation, with signs of prosthetic failure
observed in only 15 patients (4.2%); notably, in only
5 cases did we report severe prosthesis dysfunction,
and 2 of these were treated with a successful redo
TAVI.
Contemporary evidence on survival rates after
TAVI at long-term follow-up are restricted to a few
studies exploring durability of previous-generation
balloon-expandable devices. In our series of 353
consecutive patients, we found 5-year all-cause and
cardiovascular mortality rates of 55% and 28%,
respectively. To better assess the long-term durability
of TAVI, we performed a landmark analysis excluding
TABLE 3 Rehospitalization
Patients
(n ¼ 353)
Rehospitalization
(n ¼ 241)
Heart failure only 69 (19.6) 103 (42.7)
PPM implant only 42 (17.4)* 42 (17.4)
Heart failure and PPM implant 4 (1.1) 4 (1.7)
Heart failure and hemorrhagic stroke 1 (0.3) 1 (0.4)
PPM implant and cardiac ischemia 1 (0.3)† 1 (0.4)
Hemorrhagic stroke only 5 (1.4) 5 (2.1)
Ischemic stroke 15 (4.2) 16 (6.7)
Transient ischemic attack only 1 (0.3) 1 (0.4)
Cardiac ischemia only 12 (3.4)† 14 (5.8)
Vascular complications only 13 (3.7) 15 (6.2)
Other cardiovascular reasons 33 (9.3) 39 (16.2)
Values are n (%). *Denominator is 241, which represents the number of patients
without PPM at discharge. †Cardiac ischemia includes any acute coronary
syndromes, percutaneous or surgical revascularization, and angina attributable to
coronary artery disease.
PPM ¼ permanent pacemaker.
FIGURE 3 Stroke
Kaplan-Meier percentage of stroke rate. CI ¼ conﬁdence interval.
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1089patients with procedural mortality (death during the
ﬁrst 30 days). Compared with the series published by
Toggweiler et al. (6), we found better survival (49%
vs. 35%); this discrepancy may be explained by the
lower risk proﬁle of patients included in the present
analysis. Notably, most deaths were more likely
linked to patients’ comorbidities and advancing age,
as demonstrated by the low rate of cardiovascular
mortality at 5 years. Consistent with previous studies
reporting shorter-term follow-up, predictors of both
5-year all-cause and cardiovascular mortality were
generally related to baseline clinical comorbidities
(STS score, NYHA functional class III or IV, and
moderate/severe baseline MR or COPD) (4,14,15).
Among the main complications, we observed that
bleeding and stroke occurred mainly in the earliest
period after TAVI. Rehospitalization due to cardio-
vascular reasons after the procedure was an impor-
tant issue raised by this study: it was required in 46%
of patients, and among all 241 rehospitalizations,
almost one-half were due to acute heart failure.
Interestingly, several noncardiac comorbidities, such
as COPD, chronic renal failure, and diabetes mellitus,
were associated with an increased risk of repeat
hospitalization for heart failure. COPD is a well-
known comorbidity in patients hospitalized with
acute heart failure and is also associated with a worse
long-term prognosis (16,17). Similarly, diabetes mel-
litus and chronic renal insufﬁciency are commonly
associated with an increased risk of adverse out-
comes, including recurrent hospitalization due to
heart failure (18,19). Finally, concomitant moderate
or severe MR was also associated with a 2-fold
increased risk of rehospitalization for decom-
pensated acute heart failure. MR is a common ﬁnding
in patients with aortic stenosis. At the time of aortic
valve replacement, up to two-thirds of patients with
aortic stenosis have varying degrees of MR (20). Few
studies, and with discordant results, have examined
the clinical effect of pre-operative MR on outcome
after TAVI (20). However, the association between
MR and the risk of rehospitalization due to heart
failure has not been investigated yet. The results of
this analysis tend to suggest that TAVI patients with
signiﬁcant pre-operative MR may potentially beneﬁt
from a staged invasive treatment of the mitral val-
vulopathy (i.e., transcatheter edge-to-edge tech-
nique), provided that they are anatomically suitable
for that (21). However, the real clinical- and cost-
effectiveness of this strategy has to be carefully
evaluated in future studies.
TRANSCATHETER HEART VALVE PERFORMANCE.
As the duration of implanted transcatheter heartvalves increases, valve durability and dysfunction
become more crucial issues. Durability of the trans-
catheter valves has been a special concern and re-
quires systematic echocardiography follow-up at late
time points. Gurvitch et al. (22) reported on clinical
outcomes, valvular structural integrity, and hemo-
dynamic changes in 70 patients evaluated a median of
3.7 years after TAVI with a balloon-expandable valve,
conﬁrming a good medium- to long-term durability
and preserved hemodynamic function with no evi-
dence of structural failure. More recently, Toggweiler
et al. (6) extended the follow-up to 5 years. In 88
patients (29 patients alive at 5-year follow-up), they
TABLE 4 Multivariable Analysis: Death From Any Cause and
Cardiovascular Death
HR (95% CI) p Value
Death From Any Cause
Moderate or severe MR 1.49 (1.02–2.17) 0.036
NYHA functional class III–IV 1.62 (1.04–2.52) 0.033
STS score 1.602 (1.010–1.040) 0.003
Cardiovascular Death
COPD 2.13 (1.07–4.23) 0.031
Moderate or severe MR 2.87 (1.47–5.61) 0.002
CI ¼ conﬁdence interval; COPD ¼ chronic obstructive pulmonary disease; HR ¼
hazard ratio; MR ¼ mitral regurgitation; NYHA ¼ New York Heart Association;
STS ¼ Society of Thoracic Surgery.
TABLE 5 Poisson Regression: Repeat Hospitalization for Acute
Heart Failure
Multivariate Analysis
IRR (95% CI) p Value
Moderate or severe MR 2.06 (1.12–3.78) 0.020
Chronic renal failure 2.77 (1.05–7.34) 0.040
Diabetes mellitus 1.86 (1.01–3.44) 0.047
COPD 2.67 (1.42–5.02) 0.002
IRR ¼ incidence rate ratio; other abbreviations as in Table 4.
FIGURE 4 Prosthe
Time trends in transa
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1090demonstrated favorable outcomes after TAVI, with
signs of moderate prosthetic valve failure in 3.4% of
patients and no cases of severe prosthetic regurgita-
tion or stenosis. Similarly, in the Italian CoreValve
registry (7), the durability of clinical, hemodynamic,
and echocardiographic outcomes were tested at
3-year follow-up, reporting stable results over the
follow-up period. There were no cases of progression
of mild PVR to moderate or severe regurgitation. No
cases of structural valve deterioration were observed
as well.
In the present analysis, we report satisfactory long-
term valve performance in terms of transprosthetic
gradient, which remained steady over time, with only
a slight increase reported at the 5-year time point.
Signs of late signiﬁcant prosthetic valve failure atsis Performance
ortic mean gradient. TAVI ¼ transcatheter aortic valve implantation.5 years after implantation were observed in 1.4% of
population, whereas asymptomatic degeneration with
only mild stenosis was reported in 2.8% of patients.
Surgical aortic bioprostheses have shown 10-year
freedom from valvular failure in the range of 60% to
90%. Reported rates of structural valve deterioration
requiring reoperation range widely from 6% to 47%
by 12 to 20 years after surgical implantation (23–25).
At 5 years, freedom from structural failure is gener-
ally >95%, and although early failure requiring
reoperation or leading to mortality has been reported,
freedom from reoperation at 5 years is also generally
more than 95% (26,27).
Although larger studies are needed to determine
the rate of structural deterioration of transcatheter
valve at longer follow-up, the ﬁndings of this analysis
tend to suggest that at 5 years, transcatheter valves
performance compare favorably with the surgical
bioprostheses.
STUDY LIMITATIONS. The present analysis has 2
main limitations. First, echocardiographic parameters
were not evaluated by a central core laboratory.
Finally, echocardiographic data and rates of late
prosthetic failure were performed in a “survival
cohort,” with death possibly exerting a competing
risk that may have biased our results. Caution must
therefore be applied when interpreting these data.
CONCLUSIONS
Our analysis showed that TAVI with the currently
adopted CoreValve generation was associated with
sustained clinical outcomes up to 5-year follow-up,
with a low rate (1.4%) of signiﬁcant prosthetic valve
failure. The procedure appears to be an adequate and
lasting resolution of aortic stenosis in selected high-
risk patients.
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PERSPECTIVES
WHAT IS KNOWN? Data on long-term clinical
outcomes of TAVI, including valve durability and
structural integrity, remain scarce.
WHAT IS NEW? In this study, the TAVI procedure with
the CoreValve device appears to be an adequate and
lasting (up to 5 years) resolution of aortic stenosis in
selected high-risk patients.
WHAT IS NEXT? The demonstration of long-term
durability of TAVI may encourage physicians to adopt this
new technology in more patient populations.
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